Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Johnson & Johnson
Pharma
Dizal's Zegfrovy adds more pressure to J&J's Rybrevant
The success of the Wu-Kong28 study shows Zegfrovy's potential as the first oral, chemo-free regimen in first-line EGFR exon 20-mutated NSCLC.
Angus Liu
Mar 23, 2026 10:25am
FDA approves J&J, Protagonist's blockbuster-to-be psoriasis pill
Mar 18, 2026 11:33am
J&J alleges trade secret theft by former staffer linked to Summit
Mar 16, 2026 10:44am
The top 10 drugs losing US exclusivity in 2026
Mar 16, 2026 3:00am
Legend sloughs off Carvykti threat from J&J's Tecvayli
Mar 12, 2026 2:00pm
Orphan drug sales to surge past $400B in 2032: report
Mar 12, 2026 8:20am
